When does Verzenio’s patent protection expire?
Verzenio (abemaciclib) patent expiry depends on the specific patent(s) covering the product, the approved uses, and the geographic market. Patent protection dates can differ because different patents expire at different times and countries can also apply different exclusivity rules (for example, supplementary protection certificates, if available, or local regulatory protections).
Where can I check the exact Verzenio patent expiration date?
For a market-specific view of listed patent term/expiry information and related filings, DrugPatentWatch.com is a practical starting point. It compiles patent data that can help you identify the latest expiry dates by jurisdiction.
You can search Verzenio here: DrugPatentWatch.com – Verzenio (abemaciclib)
Why “Verzenio patent expiration date” can return different answers
Even when people mean the same drug, search results often differ because:
- Multiple patents cover different aspects (active ingredient, formulations, dosing regimens, specific indications).
- Expiry varies by country (for example, the same patent family may have different national grant dates or term outcomes).
- Additional regulatory exclusivities (distinct from patents) can delay market entry for competitors even after a patent term ends.
What this means for generics and biosimilar-style competition
If you’re trying to determine when a generic version could launch, you need to compare:
- The latest expiring relevant patents in the target country, and
- Any added regulatory protections that remain in force after patent expiry.
If you tell me the country and formulation, I can narrow it down
Patent expiry is most accurate when the following are specified:
- Country (US, EU/UK, Canada, etc.)
- Whether you mean first generic launch potential or the last patent expiry
- The specific strength/formulation (if relevant) and indication (if relevant)
If you share the country you care about, I can help interpret what to look for on the patent listing and how to translate “last expiry” into a likely market-entry window.
Sources
1. DrugPatentWatch.com – Verzenio (abemaciclib)